Giugliano RP, Pedersen TR, Park J-G, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017. doi: http://dx.doi.org/10.1016/S0140-6736(17)32290-0. [Epub ahead of print]
Mabuchi H. Familial hypercholesterolemia. Nihon Rinsho. 2013;71:170-187.
Japanese Ministry of Health, Labor and Welfare. International comparison of life expectancy. Tokyo, Japan: Ministry of Health, Labor and Welfare; 2016.
Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425-2437. Abstract
Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478a-3490a.
Harada-Shiba M, Arai H, Okamura T,et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2012;19:1019-1026. Abstract
Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167-2192. Abstract
Mabuchi H, Nohara A, Noguchi T, et al. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis. 2014;236:54-61. Abstract
World Health Organization (WHO). Familial hypercholesterolemia: Report of the second WHO consultation. Geneva, Switzerland; WHO; 1999.
Zhou M, Zhao D. Familial Hypercholesterolemia in Asian Populations. J Atheroscler Thromb. 2016.23:539-549. Abstract
Harada-Shiba M, Arai H, Oikawa S, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19:1043-1060. Abstract
Ohmura H, Fukushima Y, Mizuno A, et al. Estimated prevalence of heterozygous familial hypercholesterolemia in patients with acute coronary syndrome. Int Heart J. 2017; 58: 88-94. Abstract
Japan Atherosclerosis Society (JAS). Guidelines for prevention of atherosclerotic cardiovascular diseases. Tokyo, Japan: JAS; 2017.
Kastelein JJ, Ginsberg HN, Langlest G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996-3003. Abstract
Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-340. Abstract
Kiyosue A, Honarpour N, Kurtz C, et al. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117:40-47. Abstract
Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568. Abstract
Brahm AJ, Hegele RA. Combined hyperlipidemia: familial but not (usually) monogenic. Curr Opin Lipidol. 2016;27:131-140. Abstract
van Greevenbroek MM, Stalenhoef AF, de Graaf J, et al. Familial combined hyperlipidemia: from molecular insights to tailored therapy. Curr Opin Lipidol. 2014;25:176-182. Abstract
Hu M, Thomas GN, Tomlinson B. Lipid disorders in Chinese populations. Clinical Lipidol. 2011;6:549-562.
Pang RW, Tam S, Janus ED, et al. Plasma lipid, lipoprotein and apolipoprotein levels in a random population sample of 2875 Hong Kong Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on cardiovascular risk assessment. Atherosclerosis. 2006;184:438-445. Abstract
Kuang Y, Li X, Chen X, et al. Higher prevalence of elevated LDL-C than non-HDL-C and low statin treatment rate in elderly community-dwelling Chinese with high cardiovascular risk. Sci Rep. 2016;6:34268.
Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634-1639. Abstract
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626-635. Abstract
Dewey FE, Gusarova V, O'Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374:1123-1133. Abstract
Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211-221. Abstract
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397. Abstract
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574. Abstract
Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365:2255-2267. Abstract
Rosenson R, Jacobson TA, Preiss D, et al. Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia. Cardiovasc Drugs Ther. 2016;30:305-313. Abstract
Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403-410. Abstract
Sanofi and Regeneron announce positive results from first dedicated studies evaluating praluent R alirocumab in Individuals with diabetes and hypercholesterolemia [news release]. Tarrytown, NY: Sanofi; 2017. http://www.news.sanofi.us/2017-06-11-Sanofi-and-Regeneron-Announce-Positive-Results-from-First-Dedicated-Studies-Evaluating-Praluent-R-alirocumab-in-Individuals-with-Diabetes-and-Hypercholesterolemia. Accessed September 19, 2017.
Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:554-561. Abstract
Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008; 83:687-700. Abstract
Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiology. 2016;32(suppl):S35-S65.
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410-414. Abstract
Wu CC, Sy R, Tanphaichitr V, et al. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol: a multinational, multicenter, double-blind study. J Formos Med Assoc. 2002;101:478-487. Abstract
Chan P, Huang TY, Tomlinson B, et al. Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. J Clin Pharmacol. 1997;37:496-501. Abstract
Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1248-1252. Abstract
Saito Y, Goto Y, Dane A, et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb. 2003;10:329-336. Abstract
Wang KY, Ting CT. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jpn Heart J. 2001;42:725-738. Abstract
Yamamoto A, Arakawa K, Sasaki J, et al; Rosuvastatin Dose-Ranging Trialist Group. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. J Atheroscler Thromb. 2002;9:48-56. Abstract
Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315:1580-1590. Abstract
Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758-769. Abstract
Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386-1395. Abstract
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-1722. Abstract
ClinicalTrials.gov. ODYSSEY Outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab. https://clinicaltrials.gov/ct2/show/NCT01663402. Accessed September 10, 2017.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Wei Chieh Jack Tan, MD

Adjunct Assistant Professor; Deputy Head; Senior Consultant, Department of Cardiology; Director, Coronary Care Unit, National Heart Centre Singapore, Singapore, Singapore

Disclosures

Disclosure: Wei Chieh Jack Tan, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Elixir
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Medtronic, Inc.; Obus Neich; Sanofi
Received grants for clinical research from: Abbott Laboratories; Beckman Coulter, Inc.

Atsushi Hirayama, MD, PhD

Professor; Director, Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan

Disclosures

Disclosure: Atsushi Hirayama, MD, PhD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Astellas Pharma Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Chugai Pharma USA, LLC; Daiichi Sankyo, Inc.; Eisai Inc.; Kissei Pharmaceutical Co. Ltd.; Kowa Company Ltd.; Kyowa Hakko Co., Ltd.; Merck Sharp & Dohme Corp.; Novartis Pharmaceutical Corporation; Otsuka Pharmaceutical Co. Ltd.; Pfizer Inc.; Sanofi; Sanwa Kagaku Kenkyusho Co., Ltd.; Shionogi & Co., Ltd.; Takeda Pharmaceuticals North America, Inc.; Tanabe Mitsubishi Pharmaceutical Co.
Received grants for clinical research from: Astellas Pharma Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Chugai Pharma USA, LLC; Daiichi Sankyo, Inc. Dainippon Sumitomo Pharma America; Eisai Inc.; Genzyme Corporation; Goodman Co. Ltd.; Kissei Pharmaceutical Co. Ltd.; Kowa Company Ltd.; Kyowa Hakko Co., Ltd.; Medtronic, Inc.; Merck Sharpe & Dohme Corp.; Mitsubishi Tanabe Pharma Corporation; Mochida; Nihon Medi-Physics Co. Ltd.; Novartis Pharmaceuticals Corporation; Ono Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co. Ltd.; Pfizer Inc.; Sanofi; Shionogi & Co. Ltd., Takeda Pharmaceuticals North America, Inc.; Toa Eiyo Ltd.; Zeon Medical Inc.

Brian Tomlinson, MD

Professor, The Chinese University of Hong Kong, Shatin, Hong Kong

Disclosures

Disclosure: Brian Tomlinson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; EMD Serono, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; EMD Serono, Inc.; Sanofi
Received grants for clinical research from: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Roche

Sam Mirzaee, MD, MPH, FRACP

Consultant cardiologist, Research Fellow, MonashHeart, Monash University, Melbourne, Australia

Disclosures

Disclosure: Sam Mirzaee, MD, MPH, FRACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; SCM

Editor

Walid Amara, MD

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Servier
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude, Servier

Content Reviewer

Nafeez Zawahir, MD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

High Risk Dyslipidemia Management in Asia Pacific

From Medscape Education

Identification of High-Risk Dyslipidemias: From Screening to Effect of Treatment

Authors: Wei Chieh Jack Tan, MD; Atsushi Hirayama, MD, PhD; Sam Mirzaee, MD, MPH, FRACP; Brian Tomlinson, MDFaculty and Disclosures

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

Medscape Education makes these downloadable slides available solely for non-commercial use by you as a reference tool. You may not use these slides for any commercial purpose or provide these slides to any third party for such party’s use for any commercial purpose. Please refer to the Medscape Terms of Use for additional details.

PDF Downloads

Web Reprint

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Wei Chieh Jack Tan, MD

Atsushi Hirayama, MD, PhD

Brian Tomlinson, MD

Sam Mirzaee, MD, MPH, FRACP

Editor

Walid Amara, MD

Content Reviewer

Nafeez Zawahir, MD

Identification of High-Risk Dyslipidemias: From Screening to Effect of Treatment

PDF Downloads